Literature DB >> 25386929

Metformin in cancer treatment and prevention.

Daniel R Morales1, Andrew D Morris.   

Abstract

Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.

Entities:  

Keywords:  clinical trials; diabetes; epidemiology; oncology

Mesh:

Substances:

Year:  2014        PMID: 25386929     DOI: 10.1146/annurev-med-062613-093128

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  150 in total

1.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 2.  Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Authors:  M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld
Journal:  Pharmacogenomics J       Date:  2016-07-19       Impact factor: 3.550

3.  Metformin attenuates TGF-β1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF-β pathways.

Authors:  Yubo Wang; Caiyu Lin; Rui Han; Conghua Lu; Li Li; Chen Hu; Mingxia Feng; Hengyi Chen; Yong He
Journal:  3 Biotech       Date:  2020-06-03       Impact factor: 2.406

Review 4.  Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.

Authors:  Judith M Graber; Shou-En Lu; Yong Lin; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

5.  Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo.

Authors:  L Allyson Checkley; Michael C Rudolph; Elizabeth A Wellberg; Erin D Giles; Reema S Wahdan-Alaswad; Julie A Houck; Susan M Edgerton; Ann D Thor; Pepper Schedin; Steven M Anderson; Paul S MacLean
Journal:  Cancer Prev Res (Phila)       Date:  2017-02-02

6.  Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation.

Authors:  Asaf Rotem; Andreas Janzer; Benjamin Izar; Zhe Ji; John G Doench; Levi A Garraway; Kevin Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

Review 7.  Metformin, an old drug, brings a new era to cancer therapy.

Authors:  Huan He; Rong Ke; Hui Lin; Ying Ying; Dan Liu; Zhijun Luo
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

8.  Targeting liver stage malaria with metformin.

Authors:  Iset Medina Vera; Margarida T Grilo Ruivo; Leonardo F Lemos Rocha; Sofia Marques; Sangeeta N Bhatia; Maria M Mota; Liliana Mancio-Silva
Journal:  JCI Insight       Date:  2019-12-19

Review 9.  X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.

Authors:  Rossella Tricarico; Emmanuelle Nicolas; Michael J Hall; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 12.531

10.  Activation of AMP-activated protein kinase by metformin ablates angiotensin II-induced endoplasmic reticulum stress and hypertension in mice in vivo.

Authors:  Quanlu Duan; Ping Song; Ye Ding; Ming-Hui Zou
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.